S. Gonnelli et al., THE USEFULNESS OF BONE TURNOVER IN PREDICTING THE RESPONSE TO TRANSDERMAL ESTROGEN THERAPY IN POSTMENOPAUSAL OSTEOPOROSIS, Journal of bone and mineral research, 12(4), 1997, pp. 624-631
Transdermal estrogen therapy is now an accepted form of treatment for
postmenopausal osteoporosis, Ninety postmenopausal osteoporotic women
were randomized to receive either transdermal estrogen (0.05 mg/day 17
beta-estradiol) and calcium (n = 45) or calcium alone (n = 45), The s
tudy period was 2 years, Bone mineral density (BMD) at the lumbar spin
e (by dual-energy X-ray absorptiometry [DXA]) and markers of bone turn
over (alkaline phosphatase, osteocalcin, hydroxyproline, pyridinoline
cross-links) were assessed at baseline and after 1 and 2 years, In the
estrogen-treated group, BMD showed a significant increase (p < 0.001)
both after I and 2 years, with a reduction in biochemical markers, To
investigate the effectiveness of estrogen treatment of postmenopausal
osteoporosis in relation to bone turnover, we also divided the patien
ts on the basis of bone turnover, as assessed by measurement of whole
body retention (WBR) of Tc-99m-methylene diphosphonate. WBR revealed t
hat 26 patients had high bone turnover (HT) and 55 had low bone turnov
er (LT), The response to estrogen was greater in the HT patients than
in the LT patients; in fact BMD increased by 5.7 and 6.6% in HT patien
ts and by 2.6 and 2.7% in LT patients after 1 and 2 Sears, respectivel
y, In conclusion, the present study demonstrates that, while the BMD d
ecreases in the patients treated with calcium alone, 2-year treatment,
vith transdermal estrogen increases axial BMD and that the response to
estrogen treatment is influenced by bone turnover, Therefore, the eva
luation of bone turnover may be useful to identify those postmenopausa
l osteoporotic women who may especially benefit from treatment with es
trogen.